EnColl’s Patent Protected, Ultra Pure, Bioactive Enhanced Type-I Collagen Matrix for Surgical Applications in Bioactive Molecule/ Growth Factor Delivery and Stem Cell and Gene Therapies

Press Release: August 11, 2012, 2:00 PM (FREMONT, CALIFORNIA)

EnColl Corporation, a California-based Biotech corporation, announced today its breakthrough Collagen Product Development for the delivery of genes, stem cells, biomolecules, and growth factors. Using their unique, technology patent-protected technology, they have developed a superior bioactive collagen matrix for the delivery of the above-mentioned items. The bioactive collagen matrix was first formulated into their US FDA-approved product, Helicoll.

Helicoll collagen dressing was approved by the US-FDA in 2004 and is well accepted by plastic surgery, dermal surgery, orthopedic surgery, and podiatric surgery for the treatment of wounds, burns, and dermal conditions. Dr. Howard Sutkin, MD, a board-certified Plastic Surgeon at the Wound Care Center, Regional Medical Center, San Jose, California, said, “Helicoll has been used for chronic surface wounds with deep space defects, and it is noticed that the Helicoll Collagen dressing accelerates and promotes healing.” “Using Helicoll dressing on a patient,” Dr. Richard Kahn, MD, a board-certified Plastic Surgeon said, “The wound was markedly improved; it was smaller and less painful and healed in 10 weeks without surgery.” “We are excited to announce the next step in EnColl’s cutting-edge product in the fields of Drug delivery, Stem cell treatments, and Gene Therapy to tissues.

For such applications, EnColl offers the only manufacturing process which produces high purity, surgical-grade collagen with EnColl’s patented Phosphorylated modifications to the Ultra-pure collagen substratum,” said Dr. Guna, principal scientist at EnColl Corp. EnColl’s existing products (Helicoll, Hemocoll and Periodontal Plus AB) without growth factors or genes are produced, clinically evaluated, and commercially sold for human applications in non-US markets. For all medical applications, EnColl’s collagen matrix can be made in any physical form suitable for a site-specific target delivery of active components (genes, stem cells, and growth factors) for the local tissue repair or therapy. Using a patented Twice Treatment Process (TTP) and other unique purification steps, EnColl offers the only biocompatible, non-immunogenic collagen. As compared to currently available medical-grade collagens, EnColl’s collagen is the only patented high purity collagen that is without contaminants from Type III collagen, broken peptides/proteins, elastin, lipids, virus, and prions. The bioactivity of EnColl’s collagen is further enhanced by a patented phosphorylation process.

According to analysis by MarketResearch.com / Kalorama Information Division, the global market for skin wound treatment modalities in 2005 was $3.3B, growing to $5.3B by 2009, representing a compounded annual growth rate of 10 percent over the forecast period. “We aim to target the global market for Biomedical applications for Collagen, like external Medical/Surgical Applications market at greater than $12B, Internal Medical/Surgical Application of market greater than $5B; Pharmaceutical/Biotechnology Applications market estimated at greater than $ 60B. Based on the total market projection as referred by reports of market analyzers of biotech industry in US, the global market size of EnColl’s product lines in the year 2008 is projected to be in the order of $8B,” said Dr. Guna of EnColl Corp.

For more Information, please Contact:
S. Gunasekaran, PhD
President – CEO
EnColl Corp. 4576 Enterprise Street, Fremont, CA-94538, USA
e-mail: guna@encoll.com
Tel. 510-396-8581